Meta-Analysis of 27 Trials Finds Intensive BP Lowering Cuts Major CV Events 15% Per 10 mmHg Drop, No Rise in Kidney Failure

The pooled data confirmed that intensive treatment prevented 4.2 cardiovascular events per 1,000 person-years in the CKD subgroup versus 2.7 in those without CKD. Absolute risk reduction was larger among participants with baseline kidney disease because their event rates were higher, yet the relative risk reduction remained consistent across strata. Kidney failure requiring dialysis or transplant showed no increase, while transient 30-40% eGFR declines rose with greater BP lowering, likely reflecting hemodynamic shifts rather than irreversible injury.

Prior observational reports of a J-shaped curve linking very low BP to harm were not reproduced once trial-level randomization and newer data were incorporated. Earlier reviews that found no extra CV benefit in CKD were limited by smaller samples; this analysis gained power by including post-SPRINT and post-ACCORD-BP studies. The findings align with the SPRINT CKD subgroup and the 2015 NEJM primary report yet extend them to a broader set of targets and populations.

Guideline committees should now weigh these results when updating thresholds for patients with eGFR below 60. Future trials need to report longer-term kidney outcomes beyond five years and test whether the observed eGFR dips predict later progression or simply mark successful BP reduction. Implementation studies will clarify how often monitoring can distinguish reversible from progressive kidney changes in routine practice.